AI-Designed Drug Shows Early Promise in Slowing Aging
TL;DR Summary
An AI-designed drug from Insilico Medicine, rentosertib, reduced biological aging markers across six aging clocks in a 12‑week study with 42 participants, suggesting AI may modulate aging biology. However, aging clocks are debated, and this is an early-stage finding with many trials and regulatory hurdles still to come.
- Study Suggests AI-Generated Drug Could Slow Aging gizmodo.com
- Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment Nature
- Early Data Indicates an A.I.-Generated Drug Could Slow Aging The New York Times
- Insilico’s Co-CEO Has Big Hopes That Fibrosis Drug Can Reverse Aging Too WSJ
- Insilico's IPF candidate rentosertib shows anti-aging promise FirstWord Pharma
Reading Insights
Total Reads
1
Unique Readers
27
Time Saved
15 min
vs 16 min read
Condensed
98%
3,073 → 48 words
Want the full story? Read the original article
Read on gizmodo.com